Compass Pathways Shares Fall 28% on Psychedelic Competition Fears
Compass Pathways shares fell 28% Monday after Usona Institute reportedly completed its FDA application for a psilocybin treatment for major depressive disorder.
Shares of Compass Pathways (CMPS) fell 28% on Monday after rival and non-profit research organization Usona Institute reportedly completed its application to the U.S. Food and Drug Administration for a psilocybin treatment in major depressive disorder.The stock is now on track for its worst day sin…